Arch Phys Med Rehabil
- KESSLER D, Franz M, Malakouti N, Rajachandrakumar R, et al
A randomized control trial of occupational performance coaching for adults with
multiple sclerosis.
Arch Phys Med Rehabil. 2024 Jun 6:S0003-9993(24)01042.
J Neuroimmunol
- WHEELER D, Bezih M, Lannen N
Spinocerebellar ataxia masquerading as multiple sclerosis, a case report.
J Neuroimmunol. 2024;393:578385.
- YONG HYF, Batty NJ, Tottenham I, Koch M, et al
Soluble adhesion molecules: Cognitive worsening biomarkers in primary progressive
multiple sclerosis?
J Neuroimmunol. 2024;393:578384.
- RECHTMAN A, Zveik O, Haham N, Brill L, et al
A protective effect of lower MHC-II expression in MOGAD.
J Neuroimmunol. 2024;391:578351.
J Neurol Sci
- HILDEBRANDT H, Eling P
Comments on energy conservation treatments for MS-related fatigue and a new
proposal.
J Neurol Sci. 2024;461:123040.
- TRIVEDI RR, Archambault AS, Pavlak C, Gastaldi M, et al
Prevalence of anti-myelin oligodendrocyte glycoprotein antibodies across
neuroinflammatory and neurodegenerative diseases.
J Neurol Sci. 2024;461:123041.
- FERNANDES L, Coats RO, Mon-Williams M, Hafeez A, et al
A novel tool for characterising upper limb function in progressive multiple
sclerosis through kinematic assessment.
J Neurol Sci. 2024;462:123068.
- MANNI A, Oggiano F, Palazzo C, Panetta V, et al
Clinical and biological predictors of Cladribine effectiveness in Multiple
Sclerosis: A real-world, single Centre study considering a two-year interval from
year-2 dosing.
J Neurol Sci. 2024;462:123070.
- HELMLINGER B, Pinter D, Hechenberger S, Bachmaier G, et al
Evaluation of the T25FW in minimally disabled people with multiple sclerosis.
J Neurol Sci. 2024;462:123073.
Mult Scler
- KRIJNEN EA, Kouwenhoven RM, Noteboom S, Barkhof F, et al
Subtypes and location of (juxta)cortical lesions relate to cognitive dysfunction
in people with multiple sclerosis.
Mult Scler. 2024 Jun 13:13524585241260968. doi: 10.1177/13524585241260968.
- SMETS I, Versteegh M, Huygens S, Wokke B, et al
Benefits of early highly effective versus escalation treatment strategies in
relapsing multiple sclerosis estimated using a treatment-sequence model.
Mult Scler. 2024 Jun 10:13524585241258692. doi: 10.1177/13524585241258692.
- BORRELLI S, Guisset F, Vanden Bulcke C, Stolting A, et al
Enlarged perivascular spaces are associated with brain microangiopathy and aging
in multiple sclerosis.
Mult Scler. 2024 Jun 7:13524585241256881. doi: 10.1177/13524585241256881.
- PONZANO M, Signori A, Bellavia A, Carbone A, et al
Race and ethnicity in multiple sclerosis phase 3 clinical trials: A systematic
review.
Mult Scler. 2024 Jun 7:13524585241254283. doi: 10.1177/13524585241254283.
Neurology
- PFEUFFER S, Wolff S, Aslan D, Rolfes L, et al
Association of Clinical Relapses With Disease Outcomes in Multiple Sclerosis
Patients Older Than 50 Years.
Neurology. 2024;103:e209574.
- MADSEN MA, Povazan M, Wiggermann V, Lundell H, et al
Association of Cortical Lesions With Regional Glutamate, GABA, N-Acetylaspartate,
and Myoinositol Levels in Patients With Multiple Sclerosis.
Neurology. 2024;103:e209543.
PLoS One
- STEFANOVIC M, Jovanovic I, Zivkovic M, Stankovic A, et al
Pathway analysis of peripheral blood CD8+ T cell transcriptome shows differential
regulation of sphingolipid signaling in multiple sclerosis and glioblastoma.
PLoS One. 2024;19:e0305042.
- LI L, Zhang M, Gu M, Li J, et al
The causal relationship between autoimmune diseases and age-related macular
degeneration: A two-sample mendelian randomization study.
PLoS One. 2024;19:e0303170.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016